Latest AI and machine learning research in allergy & immunology for healthcare professionals.
BACKGROUND: Breast cancer (BC) is the most common malignancy afflicting women worldwide, yet the rol...
Renal cell carcinoma (RCC) is the leading cause of urinary system morbidity and mortality. Early ide...
OBJECTIVES: The aim of this analysis is to evaluate the performance and reproducibility of the Pytho...
BACKGROUND: Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents, charac...
Here, we utilized advanced bioinformatics approaches alongside experimental validation to identify k...
Sepsis-induced immunosuppression leads to poor prognosis. Circulating lymphocyte count (LC), as an e...
BACKGROUND: Uveal melanoma (UVM) is the most common intraocular malignancy in adults and exhibits po...
Recent advances in digital pathology have enabled comprehensive analyses of Whole-Slide Images (WSIs...
BACKGROUND: Ulcerative colitis (UC) is a chronic nonspecific inflammatory bowel disease of unknown e...
A growing number of diseases are now treated with immunotherapies, which consist of interventions th...
Non-small cell lung cancer (NSCLC) patient management relies on molecular analysis to determine elig...
The health of children may be adversely influenced by the air quality in schools because they are mo...
BACKGROUND: Biomechanical features show notable heterogeneity in tumor risk stratification, yet thei...
BACKGROUND: A label of betalactam (BL) allergy is estimated in around 10% of the population in their...
BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is an aggressive malignancy originating from the ...
BACKGROUND: Sjögren's disease (SjD), mucosa-associated lymphoid tissue lymphoma (MALT lymphoma), and...
The tumor immune microenvironment (TME) is pivotal in regulating cancer initiation, progression, and...
BackgroundAsthma is a common chronic respiratory disease, cardiovascular disease (CVD) mortality con...
BACKGROUND: Hepatocellular carcinoma (HCC) is a common and aggressive form of cancer. There is an in...